tirzepatide and estrogen Postmenopausal women on the GLP-1 medication (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a retrospective cohort study indicated. https://www.medpagetoday.com/endocrinology/menopause/119594 Menopause: GLP-1 Drugs, Hormone Therapy

Your metabolism shifted because muscle loss starts after 30 and it doesn't stop unless you fight for it

EvidenceBased Complementary Altern

The NF-kB pathway: ground zero for autoimmune inflammation Nuclear factor kappa B, or NF-kB, is the master switch for inflammatory gene expression

Eligibility for tirzepatide generally requires a BMI threshold (commonly 30, or 27 with at least one comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea), no personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, no active pancreatitis history, and no current pregnancy or active pregnancy plan

Embarking on a weight loss journey with semaglutide can be an exciting step toward a healthier you

Finally, we emphasize the need for integrated, multidisciplinary care pathways that coordinate hepatology, cardiology, endocrinology, and primary care to identify high-risk individuals early, tailor intensity of preventive therapies, and address the concurrent liver and CVD burden